Clinical Trial Update: Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab with Hyper-CVAD for Burkitt lymphoma and Burkitt-like lymphoma; the study is completed and results were posted in May 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt Lymphoma
• Burkitt-like Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Doxorubicin (doxorubicin)
• Rituximab (rituximab)
• Vincristine (vincristine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Burkitt's Lymphoma, Burkitt'S-like Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2018-05-16